logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Onyx Therapeutics, Inc.


USPTO Granted Patents = 50

% Expired Patents = 32.0



Forward Citations = 634

Loading Chart...
Loading Chart...

49 inventors (with patents filed for the assignee):

goldMedal Guy J Laidig (25 out of 31 patents)

silverMedal Mark Stephen Smyth (17 out of 41 patents)

bronzeMedal Kevin D Shenk (16 out of 27 patents)

4.  Han-Jie Zhou (14 out of 37 patents)

5.  Mark K Bennett (14 out of 35 patents)

6.  Pasit Phiasivongsa (12 out of 26 patents)

7.  Francesco Parlati (11 out of 21 patents)

8.  Catherine Sylvain (9 out of 65 patents)

9.  Christopher J Kirk (7 out of 8 patents)

10.  Louis C Sehl (7 out of 15 patents)

11.  Henry Johnson (5 out of 13 patents)

12.  David C Moebius (5 out of 11 patents)

13.  Congcong M Sun (5 out of 6 patents)

14.  Dustin L McMinn (5 out of 31 patents)

15.  Shabbir T Anik (4 out of 7 patents)


Core Competencies:
Protease Inhibitors
Peptide Epoxyketones
Combination Therapy
Immunoproteasome
Prodrugs
Cyclodextrin Complexation
Enzyme Inhibition
Modified Release Formulations
Biomarkers
Liposomal Compositions
Metastasis Suppression
Crystalline Compounds

50 patents:

1. 11078233 - Tripeptide epoxy ketone protease inhibitors (2021-08-03),
2. 10870889 - Immunoglobulin expression levels as biomarker for proteasome inhibitor response (2020-12-22),
3. 10682419 - Prodrugs of peptide epoxy ketone protease inhibitors (2020-06-16),
4. 10647744 - Tripeptide epoxy ketone protease inhibitors (2020-05-12),
5. RE47954 - Combination therapy with peptide epoxyketones (2020-04-20),
6. 10596222 - Combination therapy with peptide epoxyketones (2020-03-24),
7. RE47302 - Peptide epoxyketone immunoproteasome inhibitors (2019-03-18),
8. 10159746 - Cyclodextrin complexation methods for formulating peptide proteasome inhibitors (2018-12-25),
9. 10150794 - Compounds for enzyme inhibition (2018-12-11),
10. 10022326 - Liposomal compositions of epoxyketone-based proteasome inhibitors (2018-07-17),
11. 9878047 - Prodrugs of peptide epoxy ketone protease inhibitors (2018-01-30),
12. 9657058 - Compounds for enzyme inhibition (2017-05-23),
13. 9657057 - Dipeptide and tripeptide epoxy ketone protease inhibitors (2017-05-23),
14. 9511109 - Combination therapy with peptide epoxyketones (2016-12-06),
15. 9434761 - Tripeptide epoxy ketone protease inhibitors (2016-09-06),
Company Overview
Onyx Therapeutics, Inc., based in South San Francisco, specializes in the development of innovative therapies focused on proteasome inhibition. The company is engaged in advancing core technologies such as protease inhibitors and peptide epoxyketones, aiming to enhance treatment efficacy through combination therapies and modified release formulations. With a commitment to addressing complex medical challenges, Onyx Therapeutics leverages its expertise in enzyme inhibition and immunoproteasome research to create impactful therapeutic solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Onyx Therapeutics, Inc. USPTO Patent Assignee Logo
50 Patents

#31 in South San Francisco, CA

#1,650 in California

#7,009 in US

#14,013 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Onyx Therapeutics, Inc.

Forward Citations = 634

49 inventors:

goldMedal Guy J Laidig (25 out of 31 patents)

silverMedal Mark Stephen Smyth (17 out of 41 patents)

bronzeMedal Kevin D Shenk (16 out of 27 patents)

4.  Han-Jie Zhou (14 out of 37 patents)

5.  Mark K Bennett (14 out of 35 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Onyx Therapeutics, Inc.. Retrieved from https://idiyas.com/company/onyx-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…